UnitedHealthcare preimplantation genetic testing Coverage Update

Coverage Criteria and Evidence Summary

Medically Necessary PGT — Covered Indications

Medically Necessary PGT — Covered when ALL of the following are met:

All of the following must be met: The genetic medical condition, if passed onto offspring, would result in Significant Health Problems or Severe Disability, and be caused by a single gene (detectable by PGT-M) or structural changes of a parent\'s chromosome (detectable by PGT-SR).

PGT is ordered by a physician after genetic counseling.

Services limited to PGT for the specific genetic disorder and related services when provided by or under the supervision of a physician (egg retrieval, fertilization, embryo culture, embryo biopsy, cryo-preservation and short-term embryo storage < one year, and embryo transfer).

Coverage includes PGT-M for monogenic/single-gene defects when parents are carriers (both parents carriers for same autosomal recessive disorder; at least one parent carrier of autosomal dominant, sex-linked, or mitochondrial condition) and PGT-SR when at least one parent is carrier of a structural chromosome rearrangement.

PGT for HLA typing to enable hematopoietic donation to an affected sibling is covered.

PGT-M (Monogenic) Covered Criteria

PGT-M eligibility (monogenic disorders / carrier scenarios) — criteria for covered indications:

One of the following parental carrier scenarios must be present: both intended parents are carriers of the same autosomal recessive disease; at least one parent is a known carrier of an autosomal dominant, sex-linked, or mitochondrial pathogenic variant; or at least one parent is a carrier of a structural chromosome rearrangement.

The condition to be prevented must be attributable to a single gene or to structural chromosomal changes and would cause Significant Health Problems or Severe Disability in affected offspring.

Testing methodology must be appropriate for the indication (eg, PCR, targeted assays, or NGS for single-gene defects; CMA, NGS or validated methods for structural rearrangements).

PGT must be ordered after documented genetic counseling that outlines advantages, limitations, and alternatives.

PGT-SR (Structural Rearrangements) Covered Criteria

PGT-SR eligibility (structural rearrangements) — criteria for covered indications:

At least one parent is a carrier of a balanced or unbalanced structural chromosome rearrangement (eg, reciprocal translocation, Robertsonian translocation, complex/CCR) associated with increased risk of miscarriage, infertility, or affected offspring.

There is prior reproductive history or objective risk consistent with structural rearrangement impact (eg, recurrent pregnancy loss, multiple adverse pregnancy outcomes, or prior abnormal pregnancy testing), or documented carrier status by cytogenetic or molecular testing.

Use of validated laboratory methods for detection of structural abnormalities (eg, CMA, NGS, or other validated platforms) and testing performed under appropriate laboratory standards.

PGT for HLA Typing

PGT for HLA typing to enable hematopoietic donation for an affected sibling — covered when ALL of the following are met:

There is an existing affected sibling with a condition for which hematopoietic stem cell or blood product donation from a matched sibling could be curative or substantially therapeutic.

PGT is used to identify an embryo that is both free of the familial single-gene or structural disorder of concern (when applicable) and is an HLA match to the affected sibling.

Procedures are performed after genetic counseling and under physician supervision as part of an assisted reproductive cycle; related embryo manipulation and short-term storage are included as described in covered services.

Evidence-based Coverage Considerations

Evidence-based coverage considerations — summary of evidence-based conclusions and subgroup signals from clinical studies and systematic reviews:

Overall evidence does not support routine, universal use of PGT-A for all IVF patients; high-quality studies and meta-analyses yield conflicting results regarding cumulative live birth rate (CLBR) and live birth rate (LBR).

Some randomized trials and subgroup analyses suggest possible benefit of PGT-A in select subgroups (eg, advanced maternal age 35–40 years) for outcomes per transfer, but benefits are often not consistent when analyzed per intention-to-treat or by CLBR per cycle.

Registry and observational data (including donor oocyte cycles) have shown potential for decreased CLBR with PGT-A in some analyses; specifically, PGT-A has not been associated with improved outcomes in donor oocyte recipient cycles and may be associated with lower pregnancy and live birth rates in that population.

Evidence supports PGT-M and PGT-SR for preventing transmission of single-gene disorders and identifying embryos free of parental structural rearrangements; data demonstrate improved proportions of normal live births in these indicated populations.

PGT-A Clinical Effectiveness

PGT-A clinical effectiveness — summary of findings about PGT-A outcomes (limitations and conclusions):

Randomized and observational studies have not consistently demonstrated improved LBR or CLBR for the general IVF population when PGT-A is applied universally.

PGT-A may reduce miscarriage rates in some studies, but this does not uniformly translate into higher live birth rates per cycle across populations.

Clinical utility of PGT-A appears most plausible in selected cohorts (eg, recurrent implantation failure, recurrent pregnancy loss, and advanced maternal age) but further high-quality randomized trials are needed to define which patients derive net benefit in terms of CLBR.

Laboratory platform, biopsy timing, and embryo cohort availability influence outcomes; counseling should address uncertainty regarding CLBR and LBR benefits.

Mosaicism and Technology Considerations

Mosaicism and technology considerations — evidence and recommendations regarding mosaic embryos and testing platforms:

Embryo mosaicism (discordance between TE biopsy and inner cell mass) limits accuracy of PGT-A; TE biopsy may yield false positives and false negatives relative to fetal outcome.

Professional guidance (PGDIS) recommends prioritizing euploid embryos for transfer; if only mosaic embryos are available, prioritize transfers based on level of mosaicism (lower percentage preferred) and consider embryo morphology and nature of the chromosomal variation when choosing between mosaics.

Reporting of mosaicism should include relative percentage/level and be part of pre-transfer counseling; patients should be informed of potential outcomes, uncertainties, and consideration of additional testing or repeat cycles to obtain euploid embryos.

Different laboratory platforms (NGS vs CGH vs aCGH vs qPCR vs niPGT-A) show variable sensitivity/specificity; some newer noninvasive approaches show promise but require larger validation studies before broad adoption.

PGT-P (Polygenic) Guidance

PGT-P (polygenic risk) stance — clinical and ethical guidance on polygenic risk scoring for embryo selection:

PGT-P/PRS for embryo selection lacks proven clinical utility and is not recommended for routine clinical use; professional societies (ACMG, ESHG, PGDIS) advise that PGT-P should only be offered in research settings until more evidence on clinical validity, utility, and ethical implications is available.

Significant ethical, legal, and social implications exist with PGT-P, and patients must receive comprehensive counseling regarding limitations and potential harms.

Clinical Populations and Evidence Nuance

Clinical populations discussed (RIF, RPL, carriers) — who may benefit per evidence:

Patients with parental carrier status for single-gene disorders (PGT-M) or structural rearrangements (PGT-SR) — clear indication and demonstrated benefit.

Individuals with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) — evidence is mixed; some studies suggest reduced miscarriage rates or improved outcomes per transfer with PGT-A, but CLBR benefits are inconsistent and patient selection requires careful counseling.

Advanced maternal age cohorts may derive per-transfer benefit in some trials; however, benefit when measured per cycle or CLBR remains uncertain.

Selective PGT-A Use Considerations

Select use of PGT-A in advanced maternal age and select RPL cohorts — evidence nuance:

Subgroup analyses and some RCTs report improved outcomes per transfer for individuals >35 years; these signals do not consistently translate to improved outcomes per intention-to-treat or CLBR and should not be generalized to all patients.

Clinicians should consider individualized counseling, discuss uncertainty about CLBR/LBR benefits, and reserve PGT-A for select patients after informed consent.

PGT-A in Donor Oocyte Cycles

PGT-A in donor oocyte cycles — coverage stance and evidence summary:

Evidence from large registry analyses indicates that PGT-A in donor oocyte recipient cycles has not been associated with improved pregnancy or live birth rates and in some analyses was associated with lower pregnancy and live birth rates; therefore PGT-A for routine use in donor oocyte cycles is not supported.

If PGT-A is considered in a donor oocyte context, individualized counseling and clear documentation of clinical rationale are required; routine coverage is not provided.

Mosaic Embryo Reporting and Transfer Prioritization

Mosaic embryo reporting and transfer prioritization — operational guidance:

Reporting of mosaic results should include the relative percentage/level of mosaicism and be incorporated into patient counseling regarding risks and uncertainties.

When possible, prioritize transfer of euploid embryos; if only mosaic embryos are available, prioritize transfer based on level of mosaicism (lower percentage preferred) and consider embryo morphology and the specific chromosomal abnormality when deciding between mosaics.

Patients should be counseled on potential outcomes of transferring mosaic embryos, including reduced implantation rates and possibly higher miscarriage rates compared with euploid embryos, and offered options such as additional cycles of PGT-A to obtain euploid embryos or consideration of prenatal diagnostic testing if pregnancy occurs.

Laboratory and clinicians should recognize limitations of TE biopsy concordance with inner cell mass; decisions should reflect available evidence, platform-specific performance, and patient values.

Indications Deemed Medically Necessary

PGT-M and PGT-SR when identified significant reproductive risk or confirmed pathogenic germline variants; detection capability requirement noted

When PGT-M and PGT-SR are indicated and technical detection requirements:

Confirmed pathogenic variant or significant reproductive risk: PGT-M and PGT-SR are indicated when there is an identified significant reproductive risk or confirmed pathogenic germline variant in the family that would cause Significant Health Problems or Severe Disability in offspring.

Documentation of the familial pathogenic variant or parental rearrangement is required; professional society guidance supports use in these circumstances.

Detection capability requirement for PGT-SR: PGT-SR should only be used when the laboratory technique applied can detect all expected unbalanced forms of the parental chromosomal rearrangement.

Parental cytogenetic characterization (karyotype) and validated laboratory methods are required prior to PGT-SR.

Society and systematic review context for PGT-M/PGT-A/PGT-SR

Context from professional societies and systematic reviews informing covered indications:

Society guidance consensus: Multiple professional societies and systematic reviews (ASRM, ESHRE, ESHG, ACMG) provide guidance that supports PGT-M and PGT-SR for confirmed pathogenic variants or structural rearrangements, while recommending caution and research-only use for PGT-P and selective application of PGT-A.

Society statements emphasize genetic counseling, documentation, and offering prenatal confirmatory testing after PGT-based embryo transfer.

Evidence sources: Systematic reviews, RCTs (e.g., STAR), registry analyses, and cohort studies are cited and demonstrate heterogeneous results for PGT-A but consistent clinical utility for targeted PGT-M/PGT-SR in appropriately selected patients.

Refer to cited literature for study-level details and limitations.

Clinical contexts (RIF, RPL, carriers, monogenic risk)

Clinical contexts in which evidence supports targeted use of PGT:

RIF and RPL contexts: Studies report that individuals with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) may experience improved implantation or reduced miscarriage with PGT-A in some analyses, though findings vary and further RCTs are needed.

Many studies combine indications limiting definitive subgroup conclusions; individualized counseling recommended.

Carrier status and monogenic risk: Couples who are carriers of structural rearrangements or known pathogenic monogenic variants are appropriate candidates for PGT-SR or PGT-M to reduce risk of affected offspring.

Documentation of carrier status and reproductive history is required.

Advanced maternal age and selected RPL cohorts

Selective consideration of PGT-A in specific patient groups:

Advanced maternal age consideration: Evidence from meta-analyses and subgroup analyses suggests potential benefit of PGT-A for some individuals older than 35 years, particularly when biopsy is performed at blastocyst stage, but benefit is not consistent across all outcome measures and populations.age >35 years

Decision-making should include counseling on ovarian reserve, likelihood of obtaining euploid embryos, and possible impact on cumulative live birth rate.

Selected RPL cohorts: Some RPL cohorts (e.g., those meeting specific inclusion criteria in retrospective analyses) demonstrate improved outcomes with PGT-A, with greater apparent benefit in older age groups; however, evidence heterogeneity warrants cautious, individualized use.

Further high-quality randomized trials are needed to establish efficacy in RPL populations.

Applicable Codes and Coding Notes

Applicable CPT/HCPCS/Proprietary Codesmixed

0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy, per embryo tested.
0552U	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy; linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder.
0553U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced; unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested.
0554U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophectoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested.
0555U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced, unbalanced structural rearrangement; monosomy, trisomy; segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested.
81228	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization (CGH) microarray analysis.
81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis.
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis.
81479	Unlisted molecular pathology procedure.
89290	Biopsy, oocyte polar body or embryo blastomere, microtechnique; less than or equal to 5 embryos.

1–10 of 35

1/4

Updated Applicable CPT/HCPCS CodesCPT

0552U	newly added applicable code (document lists added codes)
0553U	newly added applicable code (document lists added codes)
0554U	newly added applicable code (document lists added codes)
0555U	newly added applicable code (document lists added codes)

No explicit billing or procedure codes in these chunksmixed

No codes listed

Mosaicism level preference (per PGDIS)

PGDIS mosaicism preferenceWhen choosing between mosaic embryos, preference is given to embryos with mosaicism < 40% (PGDIS 2019).

Report mosaicism levelPGDIS recommends reporting the relative percentage (level) of mosaicism to inform transfer decisions.

Prioritization guidancePrioritize euploid blastocysts; if transferring mosaic embryos, prioritize based on level over specific chromosome involvement.

Provider Requirements, Documentation, and Operational Notes

Prior Authorization

Prior Authorization and Coding

Prior authorization: Verify member-specific prior authorization (PA) requirements before ordering PGT; PA rules vary by plan and state. Providers should confirm whether a PA is required and supply any requested documentation to avoid claim denials.

Check the member-specific benefit plan and applicable federal/state mandates for PA requirements.
Confirm PA status with UnitedHealthcare prior to services.
When requesting PA, use the most current CPT/HCPCS codes (including newly added codes 0552U–0555U) to reduce administrative denials.

Documentation Required

Clinical Indication Documentation Recommended

Clinical indication documentation: Document clinical indications and rationale when ordering PGT (examples: advanced maternal age, recurrent pregnancy loss [RPL], recurrent implantation failure [RIF], known parental single-gene disorder or structural chromosomal rearrangement). Medical records may be requested to confirm the member meets clinical criteria.

Include relevant history (e.g., age, number of prior losses/failed implantations).
Specify the genetic condition targeted for PGT‑M or the chromosomal abnormality for PGT‑SR.
Document ovulation induction/controlled ovarian stimulation and planned related ART procedures.

Documentation Required

Physician Order After Genetic Counseling

Genetic counseling and physician order: PGT must be ordered by a physician after comprehensive genetic counseling. Documentation of counseling (pre-test and, when applicable, post-test) is recommended and may be requested during review.

Document that an experienced PGT genetic counselor (or other qualified genetics professional) counseled the patient regarding test limitations, alternatives, and reproductive options.
Include the physician order referencing the specific test (PGT‑M, PGT‑SR, or PGT‑A) and the targeted condition.
If mosaic results or adult-onset conditions are involved, document specialty counseling and any referrals (e.g., pediatric genetics).

Note

Routine PGT‑A Not Supported

Routine PGT‑A not supported and test limitations: Routine universal use of PGT‑A is not supported by current evidence for all IVF patients. Counsel patients on limited/variable clinical benefit and technical limitations (e.g., TE biopsy discordance, mosaicism, false positives/negatives).

Reserve PGT‑A consideration for patients with advanced maternal age or other specific clinical indications; routine use for younger, low‑risk patients is not recommended.
Inform patients about possible false results due to trophectoderm (TE) vs inner cell mass discordance and embryo mosaicism.
Discuss alternative strategies such as standard IVF without PGT‑A or repeat testing where appropriate.

Documentation Required

Confirmatory Prenatal Testing Recommended

Confirmatory prenatal diagnostic testing: Offer and document counseling about confirmatory prenatal diagnostic testing (CVS or amniocentesis) for pregnancies conceived after PGT‑M, PGT‑SR, or PGT‑A, per ACOG and ASRM recommendations.

Document that patients were offered CVS or amniocentesis to confirm embryo testing results and to screen for other fetal anomalies.
Note that confirmation is recommended because technical limitations of PGT may result in misdiagnosis.

Step Therapy

Stepwise Use Based on Age and Clinical History

Stepwise use and patient selection: Consider a stepwise approach—prioritize standard IVF and morphology-based selection for younger patients with low risk; consider PGT‑A primarily for patients with advanced maternal age, recurrent pregnancy loss, or recurrent implantation failure.

Document patient age and reproductive history to justify use of PGT‑A.
When mosaic embryos are encountered, follow society guidance to prioritize euploid embryos and use level/type of mosaicism to inform decisions.

Documentation Required

Medical Records, Validation, and Study Documentation

Documentation and study-related records: Medical records and supporting study documentation may be required for coverage review. Include test reports, laboratory validation or linkage evidence when applicable, and any study-specific documents if the testing is investigational or part of research.

Provide lab reports showing the specific PGT method and validation data when requested.
If using newer or investigational approaches (e.g., niPGT‑A), include study validation, linkage to clinical outcomes, and any protocol documentation.
Retain records of embryo biopsy, cryopreservation, and embryo transfer procedures for review.

Billing Rule

Verify Prior Authorization and Use Updated Codes

Coding updates and denial risk: Use updated CPT codes and verify coding guidance prior to submission. Administrative denials can occur if outdated or incorrect codes are used.

Confirm and use newly added CPT codes (e.g., 0552U, 0553U, 0554U, 0555U) where applicable.
Verify PA and billing rules with UnitedHealthcare; coding mismatches may lead to claim denials.

Note

Follow Member-Specific Benefit Plan

Member-specific benefit plan governs: Always check the member-specific benefit plan and applicable mandates; this policy is informational and does not guarantee coverage. In a conflict, the member-specific benefit plan controls.

Before ordering, confirm benefits, exclusions, and any state/federal mandates that may affect coverage.
When in doubt, obtain prior authorization and submit complete documentation to support medical necessity.

Definitions and Terminology

Preimplantation Genetic Testing (PGT)

DefinitionPreimplantation Genetic Testing (PGT) is a test performed to analyze DNA from oocytes (polar bodies) or embryos (cleavage stage or blastocyst) for HLA typing or genetic abnormalities.

IncludesPGT-A (aneuploidy), PGT-SR (structural rearrangements), and PGT-M (monogenic/single-gene).

SpecimenTesting may be performed on oocytes (polar bodies) or embryos at cleavage or blastocyst stage.

Significant Health Problems or Severe Disability

DefinitionSignificant Health Problems or Severe Disability: a physical or mental impairment that substantially limits one or more major life activities, expected to last at least 12 months or result in death.

Use in policyThis definition is used to determine whether a genetic condition meets coverage criteria for PGT-M or PGT-SR.

SourceFederal Government Definition for Social Security Disability Benefits (Department of Labor).

PGT-M (Preimplantation genetic testing for monogenic disorders)

DefinitionPGT-M: Preimplantation genetic testing for monogenic (single-gene) defects to prevent transmission of pathogenic germline variants to offspring.

EvidenceSystematic reviews report clinical pregnancy and live birth rates after PGT-M; PGT-M is indicated when known familial pathogenic variants pose significant reproductive risk.

OrderingPGT-M should be ordered by a physician after genetic counseling and requires confirmation of the familial pathogenic variant.

PGT-SR (Preimplantation genetic testing for structural rearrangements)

DefinitionPGT-SR: Preimplantation genetic testing for chromosomal structural rearrangements (e.g., balanced translocations) to identify unbalanced embryos for transfer decisions.

PerformanceNGS/MPS shows high concordance with karyotyping and superior detection of segmental aneuploidy and complex rearrangements compared to CGH/FISH in PGT-SR settings.

Clinical usePGT-SR may improve reproductive outcomes and assist genetic counseling for carriers of structural rearrangements.

PGT-A (Aneuploidy testing)

DefinitionPGT-A: Preimplantation genetic testing for aneuploidy (formerly PGS) — screening embryos for chromosomal number abnormalities.

Policy stanceRoutine use of PGT-A in all IVF cycles is not supported by the evidence and is excluded from benefits under this policy.

LimitationsTE biopsy-based PGT-A can yield false positives/negatives because trophectoderm may not reflect inner cell mass chromosomal status.

TE biopsy (Trophectoderm biopsy)

DefinitionTrophectoderm (TE) biopsy: removal of TE cells from blastocyst-stage embryos for genomic testing (commonly used for PGT-A/PGT-SR).

CaveatTE results may not always reflect the chromosomal status of the inner cell mass (fetus), contributing to false positives/negatives due to mosaicism.

ImplicationClinical interpretation requires counseling; some studies compare TE biopsy results with inner cell mass and show discordant mosaicism levels.

Segmental aneuploidy / mosaicism

DefinitionSegmental aneuploidy / mosaicism: de-novo partial chromosome gains or losses and mosaic patterns in embryos that can vary between TE and inner cell mass.

Clinical implicationSegmental mosaicism may lead to classification uncertainty and affect transfer decisions; detection sensitivity varies by platform (NGS, CGH, FISH).

EvidenceStudies identified numerous de-novo segmental aneuploidies and demonstrated different mosaic levels between TE and inner cell mass in some embryos.

niPGT-A (Noninvasive PGT-A)

DefinitionniPGT-A: Noninvasive PGT-A using sequencing of cell-free DNA released into embryo culture media as an alternative to TE biopsy.

StatusEarly investigational data suggest niPGT-A may have higher concordance and specificity versus TE biopsy in small studies, but larger studies are needed.

ImplicationNot yet established as standard; further research required before routine clinical use.

PGT-P (Polygenic risk / polygenic scoring)

DefinitionPGT-P: Preimplantation genetic testing using polygenic risk scores to estimate multi-gene disease risk for embryo selection.

Policy stanceEvidence for clinical utility is lacking; professional societies (ACMG) recommend PGT-P only in research settings and consider it unproven for routine clinical use.

ConcernsEthical, social, and legal issues and limited validation data preclude routine clinical application at this time.

Mosaic embryo

DefinitionMosaic embryo: an embryo composed of both euploid and aneuploid cells where the relative percentage (level) of mosaicism can influence clinical outcomes and transfer prioritization.

Level considerationsHigher-level mosaicism is associated with less favorable outcomes; relative percentage of mosaicism better predicts outcome than chromosome involved.

Transfer guidancePrioritize euploid embryos; if transferring mosaic embryos, consider level of mosaicism (e.g., <40% preferred) and provide comprehensive counseling.

Laboratory regulation (CLIA / FDA informational note)

RegulationLaboratories that perform preimplantation genetic testing are regulated under the Clinical Laboratory Improvement Amendments (CLIA).

FDA noteFDA information is provided for informational purposes; FDA approval/clearance alone is not a basis for coverage.

ReferencePolicy cites FDA/CLIA resources and notes laboratories must meet applicable regulatory requirements.

Preimplantation genetic testing (PGT) analyzes DNA from oocytes or embryos to identify single-gene defects (PGT-M), structural chromosome rearrangements (PGT-SR), or chromosomal aneuploidy (PGT-A). When indicated for known pathogenic variants or structural rearrangements, PGT can help prevent transmission of significant genetic conditions and facilitate informed embryo selection in assisted reproduction.

Eligibility and Documentation Requirements

Eligibility for covered PGT (PGT-M and PGT-SR) requires documentation that the genetic condition would result in Significant Health Problems or Severe Disability and that the risk is due to a single-gene pathogenic variant or a parental structural chromosome rearrangement. Coverage is limited to PGT ordered by a physician after genetic counseling and when performed under appropriate clinical supervision.

For PGT-M, benefits apply when both intended parents are carriers of the same autosomal recessive condition, or when at least one parent carries an autosomal dominant, sex-linked, or mitochondrial pathogenic variant that would cause significant disease in offspring. Genetic counseling and verification of the familial pathogenic variant are required prior to testing.

For PGT-SR, benefits apply when at least one parent is a carrier of a structural chromosomal rearrangement and the rearrangement places offspring at risk for significant health problems. The testing technique must be capable of detecting the expected unbalanced forms of the rearrangement.

Covered services include related IVF procedures when provided under physician supervision: egg retrieval, fertilization and embryo culture, embryo biopsy, cryopreservation and short-term embryo storage (less than one year), and embryo transfer. Documentation of procedure details and clinical indication may be required to establish eligibility.

Genetic counseling is strongly recommended and is a prerequisite for ordering PGT. Counseling should be provided by personnel experienced in PGT and the specific condition, and should document the advantages, limitations, and potential need for prenatal confirmation after PGT results.

Laboratory methods and validation are important eligibility considerations: covered PGT requires appropriate laboratory techniques (e.g., PCR, NGS, CMA) with demonstrated ability to detect the relevant variant or rearrangement. For PGT-SR, parental karyotyping to define the rearrangement is foundational.

Prior testing or documentation of the familial pathogenic variant, where applicable, is expected. Targeted mutation analysis, linkage or parental testing used in study protocols support clinical interpretation and are commonly part of PGT-M workflows when a known familial variant is present.

Eligibility considerations for PGT-A are nuanced: evidence indicates potential benefit in certain subgroups (for example some older age groups or recurrent pregnancy loss cohorts), but routine PGT-A is not supported for unselected IVF populations. Clinical judgment, counseling, and documentation of specific indications should guide testing decisions.

Providers must follow member-specific benefit plan requirements and verify applicable billing codes when requesting coverage. PGT must be ordered by a physician after genetic counseling; use the updated applicable CPT/HCPCS codes listed by the policy when submitting claims.

Operational Notes and Study-Related Documentation

Documentation Required

Counsel carriers and monogenic/structural rearrangement cases

Several studies highlight counseling implications for carriers and cases involving monogenic disorders or structural rearrangements; ensure counseling addresses expected outcomes, limitations, and reproductive options.

Document discussion of expected euploid embryo yield and impact of parental CCR/translocation.
Include anticipated success rates and potential need for additional cycles in counseling notes.

Documentation Required

Counsel on PGT-A benefits and limitations

Emphasize benefits and limitations of PGT-A during counseling, including potential subgroup benefits (e.g., older maternal age) and uncertainty for routine use.

Document discussion of limited evidence for routine PGT-A and potential risks/benefits.
Record that alternatives and expected outcomes were reviewed with the patient.

Note

Typical order origin — coordinate with IVF/REI and genetics

Orders typically originate from IVF/REI programs and should be coordinated with reproductive endocrinology/ART teams; involve genetics support when appropriate.

Ensure coordination between IVF/REI clinicians, embryology lab, and genetic counselors.
Document team members involved in the ordering and testing workflow.

Documentation Required

REI team coordination for logistics, embryology, and genetics

REI teams should coordinate logistics with embryology labs and genetics support for biopsy, testing, and result interpretation; document roles and processes in the medical record.

Record biopsy method, laboratory performing testing, and follow-up plans.
Document any referrals to genetics or pediatric genetics when indicated.

Documentation Required

Document validation and confirmation methods used in testing

Study methods report laboratory confirmation practices such as parental SNP linkage analysis and karyotyping to resolve allele dropout and confirm embryo results; document laboratory validation and confirmatory testing where relevant.

Include documentation of parental karyotype or SNP linkage analyses if performed.
Record laboratory validation methods used (e.g., NGS, aCGH) in clinical notes.

Documentation Required

Record embryo biopsy methods, blastocyst number/quality, and maternal age

Studies recommend documenting embryo biopsy methods, number and quality of blastocysts available, and maternal age as these factors affect interpretation and outcomes.

Record biopsy stage (day 3 vs blastocyst), number of blastocysts biopsied, and embryo quality.
Include maternal age in documentation supporting clinical decision-making.

Documentation Required

Include genetic counseling and specialist involvement in orders

Appropriate ordering should include documented genetic counseling and involvement of specialists knowledgeable in the condition, per society recommendations.

Document that counseling was provided by an experienced PGT genetic counselor or clinician with condition expertise.
Note any specialist consultations that informed the decision to order PGT.

Prior Authorization

Who may order — physician order after counseling required

A physician order is required after genetic counseling — reiteration that PGT must be ordered by a physician following counseling and documented accordingly.

Background, Evidence Summary, and Guidelines

Clinical evidence for PGT-A is mixed. Randomized trials such as the STAR study and multiple systematic reviews find heterogeneous results: some analyses show reduced miscarriage or improved cumulative LBR in select subgroups, but overall high-quality evidence does not support routine benefit across unselected IVF populations. Study limitations include incomplete transfers, age imbalances, and variable laboratory methods.

Evidence-based coverage considerations summarize that routine PGT-A is of uncertain benefit for the general IVF population, but subgroup signals (for example individuals >35 years or some recurrent pregnancy loss cohorts) have been reported. Test performance and clinical outcomes vary by study design, patient selection, and laboratory platform, underscoring the need to apply PGT selectively with informed counseling.

PGT encompasses testing of oocytes or embryos to identify single-gene defects (PGT-M), structural rearrangements (PGT-SR), and aneuploidy screening (PGT-A). Methods include PCR, NGS/MPS, and chromosomal microarray techniques. PGT aims to prevent transmission of significant genetic disorders and may influence IVF management such as single embryo transfer.

Research gaps and study limitations frequently cited include lack of RCTs in some areas, short duration of follow-up, heterogeneity in biopsy timing and laboratory platforms, and potential selection biases. These limitations constrain interpretation of PGT clinical utility and justify conservative coverage approaches for certain indications.

Professional society statements and reviews characterize PGT-P as unproven and raise ethical concerns. Some organizations describe embryo selection by polygenic scores as ethically contested or inappropriate for clinical application at this time, supporting restriction of PGT-P to research contexts.

Laboratories performing PGT operate under CLIA regulatory oversight and should use validated methods appropriate to the testing indication. FDA clearance or approval is informational and not a basis for coverage; laboratory validation and quality practices are emphasized for reliable PGT results.

OpenPayer

Preimplantation Genetic Testing and Related Services

Coverage Criteria and Evidence Summary

Indications Deemed Medically Necessary

Services Not Covered Under This Policy

Applicable Codes and Coding Notes

Provider Requirements, Documentation, and Operational Notes

Definitions and Terminology

Eligibility and Documentation Requirements

Operational Notes and Study-Related Documentation

Background, Evidence Summary, and Guidelines

Policy Revision History